Examining the link between kidney function and biomarkers in pulmonary hypertension
Association Between Biomarkers and Kidney Function Decline in Patients With Pulmonary Hypertension
This study is trying to see how kidney function and certain markers in urine and blood are related in adults with pulmonary hypertension to improve understanding and care for kidney issues in these patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Giessen Academic / other |
| Locations | 1 site (Giessen, Hessen) |
| Trial ID | NCT06409624 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between urinary and plasma biomarkers and changes in estimated glomerular filtration rate (eGFR) in patients with pulmonary hypertension (PH). Given that kidney disease is prevalent in approximately 35% of PH patients and is associated with worse outcomes, understanding the mechanisms connecting heart and kidney function is crucial. The study will involve inpatients aged 18 and older who are undergoing right heart catheterization, without any planned interventions. By identifying potential biomarkers, the research seeks to enhance diagnostic and prognostic capabilities for kidney disease in the context of PH.
Who should consider this trial
Good fit: Ideal candidates for this study are inpatients aged 18 and older with pulmonary hypertension undergoing right heart catheterization.
Not a fit: Patients with severe chronic kidney disease (eGFR <20 ml/min/1.73 m2) or those with active tumor disease or other significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and treatment strategies for patients with pulmonary hypertension and concurrent kidney disease.
How similar studies have performed: While the specific approach of linking biomarkers to kidney function in PH is novel, similar studies have shown the importance of biomarkers in understanding disease progression in related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inpatients aged ≥18 years * Undergoing right heart catheterization (RHC) Exclusion Criteria: * Active tumor disease requiring targeted therapy * inflammatory or autoimmune disease with renal involvement requiring systemic immunosuppressive treatment * Chronic kidney disease with eGFR \<20 ml/min/1.73 m2 * non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload * if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before RHC * prediagnosed glomerulonephritis * polycystic kidney disease * postrenal obstruction * solid organ transplantation * anticipated life expectancy of \<12 months * likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant) * pregnancy or possibility of pregnancy in the next 12 months * refusal to participate * not available for follow-up visits
Where this trial is running
Giessen, Hessen
- University Hospital Giessen and Marburg, Campus Giessen, Department of Internal Medicine II — Giessen, Hessen, Germany (Recruiting)
Study contacts
- Principal investigator: Faeq Husain-Syed, MD — University of Giessen
- Study coordinator: Faeq Husain-Syed, MD
- Email: faeq.husain-syed@innere.med.uni-giessen.de
- Phone: +49 641 985 42378
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.